Multivariable logistic regression model predicting receipt of chemotherapy
| Variable . | Odds ratio (95% confidence interval) . | Overall P value . |
|---|---|---|
| Sex | .001 | |
| Male vs female | 1.07 (1.03-1.12) | |
| Race | 0009 | |
| African American vs other | 0.84 (0.73-0.96) | |
| African American vs white | 0.85 (0.78-0.93) | |
| Other vs white | 1.02 (0.91-1.14) | |
| Median household income | <.0001 | |
| <$30 000 vs $30 000-$34 999 | 0.90 (0.83-0.97) | |
| <$30 000 vs $35 000-$45 999 | 0.90 (0.84-0.98) | |
| <$30 000 vs ≥ $46 000 | 0.80 (0.74-0.87) | |
| $30 000-$34 999 vs $35 000-$45 999 | 1.00 (0.94-1.07) | |
| $30 000-$34 999 vs ≥ $46 000 | 0.90 (0.83-0.96) | |
| $35 000-$45 999 vs ≥ $46 000 | 0.89 (0.84-0.94) | |
| Distance traveled, miles | <.0001 | |
| 5-11.9 vs 12-34.7 | 0.92 (0.86-0.98) | |
| 5-11.9 vs ≥ 34.8 | 0.82 (0.76-0.89) | |
| 5-11.9 vs 0-4.9 | 1.16 (1.09-1.23) | |
| 12-34.7 vs ≥ 34.8 | 0.89 (0.83-0.96) | |
| 12-34.7 vs 0-4.9 | 1.26 (1.18-1.34) | |
| ≥34.8 vs 0-4.9 | 1.41 (1.31-1.52) | |
| AML subtypes | <.0001 | |
| Core binding factor AML vs therapy-related AML | 2.32 (1.82-2.96) | |
| Core binding factor AML vs other intermediate/high risk | 1.43 (1.22-1.68) | |
| Core binding factor AML vs acute promyelocytic leukemia | 1.26 (1.05-1.52) | |
| Therapy-related AML vs other intermediate/high risk | 0.62 (0.51-0.74) | |
| Therapy-related AML vs acute promyelocytic leukemia | 0.54 (0.44-0.67) | |
| Other intermediate/high risk vs acute promyelocytic leukemia | 0.88 (0.80-0.97) | |
| Annual hospital volume (as a continuous variable)* | 1.02 (1.02-1.03) | <.0001 |
| Facility type | <.0001 | |
| Academic vs nonacademic | 1.51 (1.36-1.67) | |
| Age | NP | <.0001 |
| Insurance status | NP | <.0001 |
| Charlson comorbidity score | NP | <.0001 |
| Age × insurance status | Supplemental Table 1 | <.0001 |
| Age × Charlson comorbidity score | Supplemental Table 2 | <.0001 |
| Variable . | Odds ratio (95% confidence interval) . | Overall P value . |
|---|---|---|
| Sex | .001 | |
| Male vs female | 1.07 (1.03-1.12) | |
| Race | 0009 | |
| African American vs other | 0.84 (0.73-0.96) | |
| African American vs white | 0.85 (0.78-0.93) | |
| Other vs white | 1.02 (0.91-1.14) | |
| Median household income | <.0001 | |
| <$30 000 vs $30 000-$34 999 | 0.90 (0.83-0.97) | |
| <$30 000 vs $35 000-$45 999 | 0.90 (0.84-0.98) | |
| <$30 000 vs ≥ $46 000 | 0.80 (0.74-0.87) | |
| $30 000-$34 999 vs $35 000-$45 999 | 1.00 (0.94-1.07) | |
| $30 000-$34 999 vs ≥ $46 000 | 0.90 (0.83-0.96) | |
| $35 000-$45 999 vs ≥ $46 000 | 0.89 (0.84-0.94) | |
| Distance traveled, miles | <.0001 | |
| 5-11.9 vs 12-34.7 | 0.92 (0.86-0.98) | |
| 5-11.9 vs ≥ 34.8 | 0.82 (0.76-0.89) | |
| 5-11.9 vs 0-4.9 | 1.16 (1.09-1.23) | |
| 12-34.7 vs ≥ 34.8 | 0.89 (0.83-0.96) | |
| 12-34.7 vs 0-4.9 | 1.26 (1.18-1.34) | |
| ≥34.8 vs 0-4.9 | 1.41 (1.31-1.52) | |
| AML subtypes | <.0001 | |
| Core binding factor AML vs therapy-related AML | 2.32 (1.82-2.96) | |
| Core binding factor AML vs other intermediate/high risk | 1.43 (1.22-1.68) | |
| Core binding factor AML vs acute promyelocytic leukemia | 1.26 (1.05-1.52) | |
| Therapy-related AML vs other intermediate/high risk | 0.62 (0.51-0.74) | |
| Therapy-related AML vs acute promyelocytic leukemia | 0.54 (0.44-0.67) | |
| Other intermediate/high risk vs acute promyelocytic leukemia | 0.88 (0.80-0.97) | |
| Annual hospital volume (as a continuous variable)* | 1.02 (1.02-1.03) | <.0001 |
| Facility type | <.0001 | |
| Academic vs nonacademic | 1.51 (1.36-1.67) | |
| Age | NP | <.0001 |
| Insurance status | NP | <.0001 |
| Charlson comorbidity score | NP | <.0001 |
| Age × insurance status | Supplemental Table 1 | <.0001 |
| Age × Charlson comorbidity score | Supplemental Table 2 | <.0001 |
NP, not provided because of interaction.
For every single increase in number of patients treated annually in a hospital, odds of receiving chemotherapy increase by a factor of 1.02.